2030 年腎上腺素市場預測 - 按產品、分銷渠道、應用和地區劃分的全球分析

據 Stratistics MRC 預測，2023 年全球腎上腺素市場規模將達到 20.5 億美元，預測期內復合年增長率為 13.1%，到 2030 年將達到 48.7 億美元。

腎上腺素是治療多種疾病最常用的藥物和激素，包括過敏反應和 1 型超敏反應的緊急治療，例如由食物、藥物、乳膠、昆蟲叮咬和蜇傷引起的過敏反應。藥物。 它的作用是放鬆氣道肌肉並收縮血管。 注射劑有多種形式，包括皮下注射瓶和內部裝有溶液的預裝自動注射器。 如有必要，通常在出現嚴重過敏反應的第一個跡象時進行注射。 腎上腺素起效迅速，可促進呼吸、加快心跳、升高血壓、阻止蕁麻疹，並減輕面部、嘴唇和頸部的腫脹。

根據美國過敏、哮喘和免疫學學院 (ACAAI) 的數據，過敏是美國慢性病的第六大原因，造成的醫療保健費用超過 180 億美元。 每年有超過 5000 萬美國人受到過敏症的影響。

市場動態：

促進因素

過敏反應增加

過敏反應是對抗原的急性過敏反應。 它可能發生在人接觸過敏原後幾秒到幾分鐘。 腎上腺素是治療過敏反應的首選藥物。 腎上腺素通過其血管收縮作用預防或減輕上呼吸道粘膜水腫、低血壓和休克。 隨著國際上過敏反應發生率的增加，發展中國家和富裕國家對這些物品的需求都在增加。 腎上腺素市場的主要參與者正在專注於開發技術先進的注射器，以滿足這種不斷增長的需求。 此外，世界各國政府批准這些注射器的通用版本顯著加速了市場增長。

抑制因素

報銷政策不充分

一般來說，較貧窮國家的過敏反應治療方案尚不清楚。 由於過敏反應應始終被視為醫療緊急情況，因此各國政府制定了特殊要求來限制高昂的醫療援助費用。 然而，有關自動注射器報銷的法律尚有缺陷。 自動注射器在發展中國家採用緩慢的另一個原因是缺乏研發活動。 然而，替代藥物輸送方法的可用性和報銷環境的不足限制了市場的擴張。

機會：

採用人工智能

過敏反應、心血管疾病和呼吸系統疾病（哮喘）等醫療狀況的發生頻率不斷增加，導致現代治療選擇的增加。 人工智能重新創建臨床試驗並創建合成患者數據，以提供對未來結果的洞察。 這使得製藥公司能夠就哪些藥物商業化以及如何更成功、更高效地進行臨床試驗做出明智的決定。 支持人工智能的注射器簡化了自我管理，提高了患者的依從性，減少了焦慮，並提供了準確的劑量。 自動注射器領域不斷湧現的技術創新，例如具有人工智能功能的自動注射器和無針自動注射器，為市場提供了利潤豐厚的潛力。

威脅

自動注射器成本高

自動注射器用於治療醫療緊急情況中的嚴重過敏反應（過敏反應）和哮喘發作。 由於對嚴重過敏反應（如過敏反應）的有效替代療法的需求不斷增長，對這些注射劑的需求正在迅速增長。 因此，此類注射器的高價格，加上患者對有效治療選擇的需求不斷增加，以及與自動注射器相關的高自付費用，是這些產品市場滲透率低的原因之一。這就是原因。

COVID-19 的影響：

新冠疫情對全球腎上腺素市場的擴張產生了負面影響。 由於就診醫療機構的患者減少，包括過敏反應在內的各種疾病的識別和治療有所下降。 超過40%的大公司銷售額出現下滑。 此外，在COVID-19疫情期間，市場發展受到這些自動注射器供應鍊和製造商中斷的限制。 然而，許多國家政府在COVID-19大流行期間採取的控制過敏反應的措施幫助了大流行後市場的擴大。

自動注射器細分市場預計在預測期內規模最大：

由於其廣泛的優勢，自動注射器領域預計將出現利潤豐厚的增長。 自動注射器是最受歡迎的一次性彈簧加載注射器。 自動注射器用於治療緊急情況下的急性過敏反應，並進行肌肉注射。 控制哮喘發作和嚴重過敏反應（過敏反應）。 該藥物可肌肉注□□射或皮下注射。 它的作用是收縮血管和放鬆氣道肌肉。 它們還易於使用、易於查找且易於攜帶，從而創造了市場對這些產品的需求。

在預測期內，最高複合年增長率預計將出現在心臟驟停階段：

預計心臟驟停領域在預測期內將以最快的複合年增長率增長。 心臟驟停的特點是呼吸、心臟功能和意識突然喪失。 心臟將血液泵送到全身（包括大腦和肺部）的能力通常會受到損害。 心肺復蘇中用於緩解心臟驟停症狀的主要藥物是腎上腺素。 心臟驟停的患者會持續注射腎上腺素，以減少血流危險。 在心肺復蘇期間，腎上腺素的腎上腺素作用促進大腦和心肌的血流。 由於腎上腺素能夠刺激腎上腺素能受體，因此該領域的需求量很大。

份額最大的地區

預計亞太地區在預測期內將佔據最大的市場份額。 由於自動注射器採用監管政策的變化，該地區顯示出巨大的滲透率。 為了滿足這一需求，亞洲公司正在全球範圍內擴大業務。 在中國、台灣和韓國，腎上腺素公司正在擴大其技術和製藥進步。 該地區的醫療保健系統越來越依賴仿製藥來最大限度地降低成本。 該地區優秀的研發計劃和舉措、一流的醫療基礎設施以及出色的報銷實踐等因素也推動了市場需求。

複合年增長率最高的地區：

由於技術先進產品的增長，預計歐洲在預測期內將呈現最高的複合年增長率。 該地區過敏反應和心血管疾病等各種疾病的患病率不斷增加。 歐洲小麥過敏的患病率很高。 根據歐洲出版物，該地區61.6%的人有食物過敏。 該地區的人口老齡化和政府對提供負擔得起的醫療保健的堅定承諾是腎上腺素需求背後的驅動力。

主要進展

2021年11月，Mylan N.V.和輝瑞公司旗下子公司Upjohn收購了Viatris Inc.，在全球範圍內開發中樞神經系統、麻醉、傳染病和心血管疾病等治療領域的產品，成立了一家全球製藥公司。

2021年10月，博世健康公司在加拿大推出了Emerald注射液0.3mg和0.5mg，用於緊急治療過敏反應。 該產品的推出為加拿大的過敏反應創造了一種新的治療選擇。

2021 年 5 月，Kaleo, Inc. 宣佈在加拿大推出 Araject 自動注射器。 此次推出為加拿大患者提供了一系列過敏反應治療選擇。

2019 年 8 月，梯瓦製藥工業公司 (Teva Pharmaceutical Industries) 宣佈在美國上市經 FDA 批准的仿製藥 EpiPen Jr(R) 1（腎上腺素注射液，USP）0.15mg 自動注射器。

2019 年 7 月，諾華宣佈在美國零售推出 SYMJEPI(TM)（腎上腺素）0.3mg 和 0.15mg 注射劑，並立即在全國各地藥店上市，成人和兒童均可購買。

報告內容

• 區域和國家級市場份額評估
• 給新進入者的戰略建議
• 2021 年、2022 年、2023 年、2026 年和 2030 年的綜合市場數據
• 市場趨勢
• 根據市場預測提出關鍵業務領域的戰略建議
• 繪製主要總體趨勢的競爭格局
• 公司簡介，包括詳細的戰略、財務狀況和最新發展
• 供應鏈趨勢映射最新技術趨勢

免費定制服務：

訂閱此報告的客戶將獲得以下免費自定義選項之一：

• 公司簡介
  • 對其他市場參與者（最多 3 家公司）進行全面分析
  • 主要公司的SWOT分析（最多3家公司）
• 區域細分
  • 根據客戶興趣對主要國家/地區的市場估計/預測/複合年增長率（注：基於可行性檢查）
• 競爭基準測試
  • 根據產品組合、地域分佈和戰略聯盟對主要參與者進行基準測試

內容

第 1 章執行摘要

第 2 章前言

• 概述
• 利益相關者
• 調查範圍
• 調查方法
  • 數據挖掘
  • 數據分析
  • 數據驗證
  • 研究方法
• 調查來源
  • 主要研究來源
  • 二手研究來源
  • 假設

第 3 章市場趨勢分析

• 促進因素
• 抑制因素
• 機會
• 威脅
• 產品分析
• 應用分析
• 新興市場
• 新冠肺炎 (COVID-19) 的影響

第 4 章波特五力分析

• 供應商的議價能力
• 買家的議價能力
• 替代品的威脅
• 新進入者的威脅
• 競爭公司之間存在敵對關係

第 5 章全球腎上腺素市場：按產品

• 自動注射器
• 預灌封注射器
• 安瓿和小瓶

第 6 章全球腎上腺素市場：按分銷渠道劃分

• 網上藥店
• 醫院藥房
• 零售藥店

第 7 章全球腎上腺素市場：按應用分類

• 淺表出血
• 過敏反應
• 呼吸系統疾病
• 心臟驟停
• 其他用途

第 8 章全球腎上腺素市場：按地區

• 北美
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 意大利
  • 法國
  • 西班牙
  • 歐洲其他地區
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳大利亞
  • 新西蘭
  • 韓國
  • 亞太地區其他地區
• 南美洲
  • 阿根廷
  • 巴西
  • 智利
  • 南美洲其他地區
• 中東和非洲
  • 沙特阿拉伯
  • 阿拉伯聯合酋長國
  • 卡塔爾
  • 南非
  • 其他中東和非洲地區

第 9 章主要進展

• 合同、夥伴關係、協作和合資企業
• 收購與合併
• 推出新產品
• 業務擴展
• 其他關鍵策略

第 10 章公司簡介

• Teva Pharmaceutical Industries Ltd.
• Abbott Laboratories
• Novartis AG
• Amneal Pharmaceuticals
• Viatris Inc
• Lincoln Medical Centre Ltd.
• Kaleo Inc
• Aurum Pharma Lab
• Bausch Health Companies
• Medeca Pharma AB
• Antares Pharma, Inc.
• Mylan N.V.
• Impax Laboratories LLC
• Adamis Pharmaceuticals Corporation
• Amedra Pharmaceuticals
• ALK Abello A/S
• Sanofi S.A.
• Grand Pharma
• Harvest Pharmaceuticals
• Bioprojet Pharma

According to Stratistics MRC, the Global Epinephrine Market is accounted for $2.05 billion in 2023 and is expected to reach $4.87 billion by 2030 growing at a CAGR of 13.1% during the forecast period. Epinephrine is one of the most often used medications and hormones for treatment in various situations, including emergency treatment of type 1 hypersensitivity reactions such as anaphylaxis and allergic reactions brought on by foods, medicines, latex, insect bites, or stings. It functions by relaxing the airway muscles and constricting the blood vessels. The injection is offered in a variety of forms, including vials for subcutaneous injection, prefilled automated injection devices that already have the solution inside, and others. At the first indication of a severe allergic response, the injection is often administered as needed. Epinephrine acts swiftly to enhance breathing, speed up the heart, boost blood pressure, stop hives, and lessen facial, lip, and neck swelling.

According to the American College of Allergy, Asthma & Immunology (ACAAI), allergies are among the 6th leading causes of chronic diseases in the U.S. and have health expenditures of more than USD 18.00 billion. Also, more than 50 million Americans suffer from allergies every year.

Market Dynamics:

Driver:

Growing prevalence of anaphylaxis

Anaphylaxis is an acute allergic reaction to an antigen. It might occur seconds or minutes after the patient is exposed to an allergen. The first choice drug for anaphylaxis therapy is epinephrine. It avoids or lessens upper airway mucosal edema, hypotension, and shock by vasoconstrictor actions. Both developing and affluent nations are seeing an increase in demand for these items as anaphylaxis rates raise internationally. Major epinephrine market companies are concentrating on creating technologically sophisticated injectors in order to meet this expanding demand. Additionally, the approval of the generic version of these injectors by governments from different nations has substantially accelerated the market growth.

Restraint:

Inadequate reimbursement policies

People are generally unaware of the anaphylactic treatment choices in poor nations. Since it should always be handled as a medical emergency, the government provides particular requirements to help reduce the high cost of medical assistance. However, the laws governing auto-injector reimbursement are insufficient. Another reason for the poor uptake of auto-injectors in developing nations is a lack of R&D activity. However, the availability of substitute medication delivery methods and the inadequate reimbursement environment are limiting the market expansion.

Opportunity:

Adoption of AI

Modern therapy choices have increased due to the increasing frequency of medical illnesses involving anaphylaxis, cardiovascular diseases, respiratory diseases (asthma), and others. AI replicates clinical trials and offers insights into prospective outcomes by producing synthetic patient data. Informed judgments on which medications to commercialize and how to create clinical trials that are more successful and efficient can thus be made by pharmaceutical firms. AI-enabled injectors make self-administration simple, boost patient compliance, lessen anxiety, and provide precise dosage. Growing innovations in auto-injectors, such as those with AI capabilities and needle-free auto-injectors are opening up the lucrative potential for the marketplace.

Threat:

High cost of auto-injectors

Auto-injectors are used to treat severe allergic responses (anaphylaxis) and asthma attacks during medical emergencies. The demand for these injections is rising quickly because to the growing need for efficient treatment alternatives for severe allergic responses, such as anaphylaxis. Thus, the high price of these types of injectors, coupled with patients' growing need for effective treatment choices and the higher out-of-pocket costs related to the auto-injectors, are partially responsible for the less worthy market penetration of these products.

COVID-19 Impact:

The corona epidemic had a detrimental effect on the expansion of the epinephrine market worldwide. The identification and treatment of various disorders, including anaphylaxis, declined as a result of the decrease in patient visits to healthcare facilities. More than 40% of major firms saw sales declines. Additionally, during the COVID-19 epidemic, the market's development was constrained by disruptions in the supply chain and the manufacturers of these auto-injectors. However, the measures implemented by governments of many nations for the control of allergic responses during the COVID-19 pandemic helped the market's expansion in the post-pandemic period.

The auto-injectors segment is expected to be the largest during the forecast period:

The auto-injectors segment is estimated to have a lucrative growth, due to its wide range of benefits. It is the most prevalent variety of disposable, single-use, spring-loaded syringe. Auto-injectors can be used to treat acute anaphylaxis in cases of urgency and delivered intramuscularly. It manages asthma episodes and severe allergic responses (anaphylaxis). This medicine is injected either into a muscle or subcutaneously. It functions by contracting the blood vessels and relaxing the muscles of the airways. They are also simple to use, easy to find, and easy to transport, thereby creating demand for these products in the market.

The cardiac arrest segment is expected to have the highest CAGR during the forecast period:

The cardiac arrest segment is anticipated to witness the fastest CAGR growth during the forecast period. Cardiac arrest is characterized by an abrupt loss of respiration, cardiac function, and consciousness. The heart's ability to pump blood across the body, including the brain and lungs, is typically disrupted. The main medication used in CPR to reverse the symptoms of cardiac arrest is epinephrine. Epinephrine is continuously infused into the patient during cardiac arrest to lower the danger of blood flow. During CPR, the adrenergic effects of epinephrine boost cerebral and myocardial blood flow. Its abilities to stimulate -adrenergic receptors are fuelling the segment demand.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period. This region has a significant prevalence owing to modifying regulatory policies for the adoption of auto-injectors. To fulfil the demand, Asian businesses are growing their worldwide footprint. In China, Taiwan, and South Korea, epinephrine enterprises are expanding technological and medicinal advances. Health systems across the region are leveraging generic medications increasingly to minimize costs. The market demand is also being fuelled by factors like superior R&D programs and efforts, first-rate healthcare infrastructure, and superior reimbursement practices in the area.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to the growth of technologically advanced products. There is raising prevalence of various disorders such as anaphylaxis, cardiovascular diseases, and others in this region. Europe has a high prevalence of wheat allergies. 61.6% of people in the region, according to various European publications, have food allergies. The region's elderly population and a stronger government commitment to providing affordable healthcare are driving forces behind the need for epinephrine.

Key players in the market

Some of the key players profiled in the Epinephrine Market include Teva Pharmaceutical Industries Ltd., Abbott Laboratories, Novartis AG, Amneal Pharmaceuticals, Viatris Inc, Lincoln Medical Centre Ltd., Kaleo Inc, Aurum Pharma Lab, Bausch Health Companies, Medeca Pharma AB, Antares Pharma, Inc., Mylan N.V., Impax Laboratories LLC, Adamis Pharmaceuticals Corporation, Amedra Pharmaceuticals, ALK Abello A/S, Sanofi S.A., Grand Pharma, Harvest Pharmaceuticals and Bioprojet Pharma.

Key Developments:

In November 2021, Mylan N.V. and Upjohn, Pfizer Inc.'s division formed a global pharmaceutical company called Viatris Inc. to develop products in therapeutic areas such as central nervous system and anaesthesia, infectious disease, and cardiovascular diseases around the world.

In October 2021, Bausch Health Companies Inc. launched Emerade injection of dosages 0.3mg and 0.5mg in Canada for the emergency treatment of anaphylactic reactions in patients. This product launch created a new treatment option for anaphylaxis in Canada.

In May 2021, Kaleo, Inc. announced the availability of ALLERJECT auto-injector injection in Canada. With this availability, Canadian patients could access different treatment options for anaphylaxis.

In August 2019, Teva Pharmaceutical Industries announced the availability of the FDA-approved generic version of EpiPen Jr®1 (epinephrine injection, USP) Auto-Injector, 0.15 mg, in the U.S. The product is available in most retail pharmacies, and the Wholesale Acquisition Cost is $3002 for a 2-pack.

In July 2019, Novartis announced the US retail launch of SYMJEPI™ (epinephrine) 0.3 mg and 0.15 mg Injections, making both the adult and paediatric doses immediately available in local pharmacies across the nation.

Products Covered:

• Auto-injector
• Prefilled Syringe
• Ampoules & Vials

Distribution Channels Covered:

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

Applications Covered:

• Superficial Bleeding
• Anaphylaxis
• Respiratory Disorders
• Cardiac Arrest
• Other Applications

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Epinephrine Market, By Product

• 5.1 Introduction
• 5.2 Auto-injector
• 5.3 Prefilled Syringe
• 5.4 Ampoules & Vials

6 Global Epinephrine Market, By Distribution Channel

• 6.1 Introduction
• 6.2 Online Pharmacies
• 6.3 Hospital Pharmacies
• 6.4 Retail Pharmacies

7 Global Epinephrine Market, By Application

• 7.1 Introduction
• 7.2 Superficial Bleeding
• 7.3 Anaphylaxis
• 7.4 Respiratory Disorders
• 7.5 Cardiac Arrest
• 7.6 Other Applications

8 Global Epinephrine Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Teva Pharmaceutical Industries Ltd.
• 10.2 Abbott Laboratories
• 10.3 Novartis AG
• 10.4 Amneal Pharmaceuticals
• 10.5 Viatris Inc
• 10.6 Lincoln Medical Centre Ltd.
• 10.7 Kaleo Inc
• 10.8 Aurum Pharma Lab
• 10.9 Bausch Health Companies
• 10.10 Medeca Pharma AB
• 10.11 Antares Pharma, Inc.
• 10.12 Mylan N.V.
• 10.13 Impax Laboratories LLC
• 10.14 Adamis Pharmaceuticals Corporation
• 10.15 Amedra Pharmaceuticals
• 10.16 ALK Abello A/S
• 10.17 Sanofi S.A.
• 10.18 Grand Pharma
• 10.19 Harvest Pharmaceuticals
• 10.20 Bioprojet Pharma

List of Tables

• Table 1 Global Epinephrine Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Epinephrine Market Outlook, By Product (2021-2030) ($MN)
• Table 3 Global Epinephrine Market Outlook, By Auto-injector (2021-2030) ($MN)
• Table 4 Global Epinephrine Market Outlook, By Prefilled Syringe (2021-2030) ($MN)
• Table 5 Global Epinephrine Market Outlook, By Ampoules & Vials (2021-2030) ($MN)
• Table 6 Global Epinephrine Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 7 Global Epinephrine Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 8 Global Epinephrine Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 9 Global Epinephrine Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 10 Global Epinephrine Market Outlook, By Application (2021-2030) ($MN)
• Table 11 Global Epinephrine Market Outlook, By Superficial Bleeding (2021-2030) ($MN)
• Table 12 Global Epinephrine Market Outlook, By Anaphylaxis (2021-2030) ($MN)
• Table 13 Global Epinephrine Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
• Table 14 Global Epinephrine Market Outlook, By Cardiac Arrest (2021-2030) ($MN)
• Table 15 Global Epinephrine Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 16 North America Epinephrine Market Outlook, By Country (2021-2030) ($MN)
• Table 17 North America Epinephrine Market Outlook, By Product (2021-2030) ($MN)
• Table 18 North America Epinephrine Market Outlook, By Auto-injector (2021-2030) ($MN)
• Table 19 North America Epinephrine Market Outlook, By Prefilled Syringe (2021-2030) ($MN)
• Table 20 North America Epinephrine Market Outlook, By Ampoules & Vials (2021-2030) ($MN)
• Table 21 North America Epinephrine Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 22 North America Epinephrine Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 23 North America Epinephrine Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 24 North America Epinephrine Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 25 North America Epinephrine Market Outlook, By Application (2021-2030) ($MN)
• Table 26 North America Epinephrine Market Outlook, By Superficial Bleeding (2021-2030) ($MN)
• Table 27 North America Epinephrine Market Outlook, By Anaphylaxis (2021-2030) ($MN)
• Table 28 North America Epinephrine Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
• Table 29 North America Epinephrine Market Outlook, By Cardiac Arrest (2021-2030) ($MN)
• Table 30 North America Epinephrine Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 31 Europe Epinephrine Market Outlook, By Country (2021-2030) ($MN)
• Table 32 Europe Epinephrine Market Outlook, By Product (2021-2030) ($MN)
• Table 33 Europe Epinephrine Market Outlook, By Auto-injector (2021-2030) ($MN)
• Table 34 Europe Epinephrine Market Outlook, By Prefilled Syringe (2021-2030) ($MN)
• Table 35 Europe Epinephrine Market Outlook, By Ampoules & Vials (2021-2030) ($MN)
• Table 36 Europe Epinephrine Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 37 Europe Epinephrine Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 38 Europe Epinephrine Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 39 Europe Epinephrine Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 40 Europe Epinephrine Market Outlook, By Application (2021-2030) ($MN)
• Table 41 Europe Epinephrine Market Outlook, By Superficial Bleeding (2021-2030) ($MN)
• Table 42 Europe Epinephrine Market Outlook, By Anaphylaxis (2021-2030) ($MN)
• Table 43 Europe Epinephrine Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
• Table 44 Europe Epinephrine Market Outlook, By Cardiac Arrest (2021-2030) ($MN)
• Table 45 Europe Epinephrine Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 46 Asia Pacific Epinephrine Market Outlook, By Country (2021-2030) ($MN)
• Table 47 Asia Pacific Epinephrine Market Outlook, By Product (2021-2030) ($MN)
• Table 48 Asia Pacific Epinephrine Market Outlook, By Auto-injector (2021-2030) ($MN)
• Table 49 Asia Pacific Epinephrine Market Outlook, By Prefilled Syringe (2021-2030) ($MN)
• Table 50 Asia Pacific Epinephrine Market Outlook, By Ampoules & Vials (2021-2030) ($MN)
• Table 51 Asia Pacific Epinephrine Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 52 Asia Pacific Epinephrine Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 53 Asia Pacific Epinephrine Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 54 Asia Pacific Epinephrine Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 55 Asia Pacific Epinephrine Market Outlook, By Application (2021-2030) ($MN)
• Table 56 Asia Pacific Epinephrine Market Outlook, By Superficial Bleeding (2021-2030) ($MN)
• Table 57 Asia Pacific Epinephrine Market Outlook, By Anaphylaxis (2021-2030) ($MN)
• Table 58 Asia Pacific Epinephrine Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
• Table 59 Asia Pacific Epinephrine Market Outlook, By Cardiac Arrest (2021-2030) ($MN)
• Table 60 Asia Pacific Epinephrine Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 61 South America Epinephrine Market Outlook, By Country (2021-2030) ($MN)
• Table 62 South America Epinephrine Market Outlook, By Product (2021-2030) ($MN)
• Table 63 South America Epinephrine Market Outlook, By Auto-injector (2021-2030) ($MN)
• Table 64 South America Epinephrine Market Outlook, By Prefilled Syringe (2021-2030) ($MN)
• Table 65 South America Epinephrine Market Outlook, By Ampoules & Vials (2021-2030) ($MN)
• Table 66 South America Epinephrine Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 67 South America Epinephrine Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 68 South America Epinephrine Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 69 South America Epinephrine Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 70 South America Epinephrine Market Outlook, By Application (2021-2030) ($MN)
• Table 71 South America Epinephrine Market Outlook, By Superficial Bleeding (2021-2030) ($MN)
• Table 72 South America Epinephrine Market Outlook, By Anaphylaxis (2021-2030) ($MN)
• Table 73 South America Epinephrine Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
• Table 74 South America Epinephrine Market Outlook, By Cardiac Arrest (2021-2030) ($MN)
• Table 75 South America Epinephrine Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 76 Middle East & Africa Epinephrine Market Outlook, By Country (2021-2030) ($MN)
• Table 77 Middle East & Africa Epinephrine Market Outlook, By Product (2021-2030) ($MN)
• Table 78 Middle East & Africa Epinephrine Market Outlook, By Auto-injector (2021-2030) ($MN)
• Table 79 Middle East & Africa Epinephrine Market Outlook, By Prefilled Syringe (2021-2030) ($MN)
• Table 80 Middle East & Africa Epinephrine Market Outlook, By Ampoules & Vials (2021-2030) ($MN)
• Table 81 Middle East & Africa Epinephrine Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 82 Middle East & Africa Epinephrine Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 83 Middle East & Africa Epinephrine Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 84 Middle East & Africa Epinephrine Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 85 Middle East & Africa Epinephrine Market Outlook, By Application (2021-2030) ($MN)
• Table 86 Middle East & Africa Epinephrine Market Outlook, By Superficial Bleeding (2021-2030) ($MN)
• Table 87 Middle East & Africa Epinephrine Market Outlook, By Anaphylaxis (2021-2030) ($MN)
• Table 88 Middle East & Africa Epinephrine Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
• Table 89 Middle East & Africa Epinephrine Market Outlook, By Cardiac Arrest (2021-2030) ($MN)
• Table 90 Middle East & Africa Epinephrine Market Outlook, By Other Applications (2021-2030) ($MN)